Fingertip Pulse Oximeter MightySat™ Adult

Features

• 1st and Only FDA Cleared over-the-counter (OTC) Fingertip Pulse Oximeter for medical use without a prescription. Kit includes: MightySat Rx device, lanyard, batteries, and drawstring pouch.
• The MightySat is comfortable and easy to use, has a flexible grip for greater comfort, provides a rotational, easy-to-read OLED screen
• An easy-to-use app enables you to track your results and share them with your loved ones or your healthcare provider. See patterns & trends, and know when your health values are out of optimal range.
• Powered by Masimo Signal Extraction Technology® (SET®), MightySat Medical features the same technology trusted by leading hospitals and proven to be accurate under conditions where other pulse oximeters fail.
• Masimo SET Pulse Oximetry has been shown to have unrivaled accuracy and reliability in more than 100 clinical studies. It is the primary pulse oximetry at all top 10 U.S. hospitals (as of 2024) and monitors more than 200 million patients a year globally.
• Accurate During Motion. Before Masimo SET® pulse oximetry, false alarm rates were high, often due to motion and low perfusion. With Masimo SET®, the rate of false alarms dropped by more than 80% and yet true alarm detection improved significantly.
• Accurate During Low Perfusion. A recent peer-reviewed study found that for Masimo SET® SpO2, ARMS* accuracy was 1.37% in all subjects with normal perfusion and 1.64% in all subjects with low perfusion
• Accurate on All Skin Tones. A peer-reviewed publication demonstrated that Masimo RD SET sensors had only a 0.15% difference in bias between dark- and light-skinned subjects, which is not clinically significant because pulse oximeters only measure in whole numbers. Further analysis showed that RD SET accurately measured SpO2 for both Black and White subjects not only when perfusion was normal but also during low perfusion.
• Masimo SET® saves lives. A study conducted over 10 years on general floor patients being monitored with Masimo SET® while recovering from surgery found zero preventable deaths or brain damage from opioid-induced respiratory depression. Another study has shown that use of SET® led to an 80% reduction in the rate of retinopathy of prematurity (ROP, an eye disorder that can cause blindness in premature babies). Of particular note, in multiple studies, involving more than 300,000 newborns, use of SET® as part of screening for critical congenital heart disease (CCHD) has been shown to significantly improve screening sensitivity.

More Information

• Introduction Video - MightySat Fingertip Pulse Oximeter
• Video - MightySat Outperforms, Comparison